Akeso highlights phase III ivonescimab data in biliary tract cancer among 30 studies slated for ESMO 2026

HONG KONG — Akeso, Inc. (9926.HK) announced on Sept. 21, 2026, that nearly 30 clinical studies featuring its bispecific antibodies have been selected for presentation at the European Society for Medical Oncology (ESMO) Congress, highlighted by a late-breaking abstract detailing phase III overall survival data for ivonescimab in first-line biliary tract cancer (PR Newswire). The data presentations position the company's pipeline assets for broader clinical scrutiny as global oncology portfolios compete for late-stage differentiation.

Strategic Context

The disclosures slated for the ESMO Congress encompass a broad cross-section of Akeso's clinical pipeline, centered on its portfolio of globally first-in-class bispecific antibodies. The inclusion of an overall survival phase III dataset as a late-breaking abstract places primary emphasis on the company's lead asset, ivonescimab, targeting biliary tract cancer in the first-line setting. Clinical development milestones of this scale carry direct implications for partnership valuations and licensing structures within the oncology sector, where phase III overall survival readouts serve as critical valuation inflection points for cross-border asset transactions.

Forward Outlook

Operators, licensing executives, and life sciences allocators will monitor the full data disclosures at the ESMO Congress for granular efficacy and safety metrics. The breadth of the nearly 30 presentations will provide further visibility into the development trajectory of Akeso's broader bispecific antibody platform beyond the lead biliary tract cancer indication.